The professor of hematology at University of Lille and chair of LYSA shared updated data from the TRANSCEND-FL trial.
“So far most of the responses are durable and we have a very good overall survival with only 1 patient dying. We need more follow up because the data are not mature bond one year and we should have that next year. But it’s really encouraging.”
Patients with high-risk relapsed/refractory follicular lymphoma (FL) receiving CD19-targeted chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi, Bristol Myers Squibb) in the second line treatment achieved high complete response rates with durable remissions.
These updated data from the TRANSCEND FL trial (NCT04245839) were presented in a poster at the 2023 American Society of Hematology (ASH) Annual Meeting & Exposition, held December 9-12, in San Diego, California by Franck Morschhauser, MD, PhD, professor, hematology, University of Lille and Hospital Claude Huriez, and chair, Lymphoma Study Association (LYSA). The data may support liso-cel's expansion to treating earlier line patients with high-risk disease.
CGTLive spoke with Morschhauser to learn more about the positive outcomes seen in the earlier line setting with liso-cel treatment for indolent lymphoma. Although further data are now available, longer follow-up still remains to be done to see how the therapy fares in the long term. He also shared the safety profile, which was comparable to other studies, with low rates of severe cytokine release syndrome, cytopenias, or severe infections.